Dr. Ashish Sarraju and Dr. C. Michael Gibson Discuss: CTX310 (CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results from Phase 1b Trial) November 9, 2026 Disclosures: TBD
Dr. Wei Zhang and Dr. C. Michael Gibson Discuss: SUPERIOR (Sacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled Trial) November 8, 2026 Disclosures: TBD
Dr. Wei Zhang and Dr. C. Michael Gibson Discuss: Angiotensinogen RNA Interference with LDR2402 for Hypertension November 8, 2026 Disclosures: TBD
Dr. Sharine Wittkopp and Dr. C. Michael Gibson Discuss: Cleaner Air for Lower Cardiometabolic Risk: A Randomized, Double-Blind, Sham-Controlled Trial of Air Pollution Reduction November 8, 2026 Disclosures: TBD
Dr. Barry Borlaug and Dr. C. Michael Gibson Discuss: Semaglutide Ameliorates the Seminal Hemodynamic Features of Obesity-Related HFpEF: A Placebo Controlled Randomized Clinical Trial November 8, 2026 Disclosures: TBD
Dr. Gregory Lewis and Dr. C. Michael Gibson Discuss: IRONMET-HFpEF (Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Trial Primary Results) November 8, 2026
Dr. Aish Sinha, Dr. Divaka Perera and Dr. C. Michael Gibson Discuss: CHIP-BCIS3 (Periprocedural Myocardial Injury, Microaxial Flow Pump Use and Cardiovascular Death After Complex Percutaneous Coronary Intervention: Insights from a Pre-Specified Analysis of the CHIP-BCIS3 Trial) November 7, 2026 Disclosures: TBD
Dr. Jordana Cohen and Dr. C. Michael Gibson Discuss: REDUCE (A Randomized Controlled Trial of Spironolactone-Based Blood Pressure Management After Stroke) November 7, 2026 Disclosures: TBD
Dr. Lindsey Rosman and Dr. C. Michael Gibson Discuss: Rethinking Atrial Fibrillation (AF) Burden: AF Density Further Stratifies Heart Failure Risk in a Nationwide Cohort of Patients with Cardiac Devices November 7, 2026 Disclosures: TBD
Dr. Behnood Bikdeli and Dr. C. Michael Gibson Discuss: HI-PRO (Apixaban vs Placebo to Prevent Recurrences in Provoked Venous Thromboembolism With Enduring Risk Factors: One-Year Extension Results From the HI-PRO Trial) November 7, 2026 Disclosures: TBD
